Supplementary Table S1: Dose distribution for topiramate/placebo during the first 6 weeks of the double-blind treatment phase (topiramate uptitration phase)

| Dose   | Erenumab group (Topiramate placebo) (N=388) | Topiramate group (Topiramate verum) (N=388) |
|--------|---------------------------------------------|---------------------------------------------|
|        | Day 1                                       |                                             |
| 25 mg  | 387 (100* 0%)                               | 388 (100* 0%)                               |
| 50 mg  | 0                                           | 0                                           |
| 75 mg  | 0                                           | 0                                           |
| 100 mg | 0                                           | 0                                           |
| missing| 1                                           | 0                                           |
|        | Week 1                                      |                                             |
| 25 mg  | 25 (6* 6%)                                  | 44 (11* 8%)                                 |
| 50 mg  | 355 (93* 4%)                                | 330 (88* 2%)                                |
| 75 mg  | 0                                           | 0                                           |
| 100 mg | 0                                           | 0                                           |
| missing| 8                                           | 14                                          |
|        | Week 2                                      |                                             |
| 25 mg  | 6 (1* 6%)                                   | 11 (3* 2%)                                  |
| 50 mg  | 59 (15* 9%)                                 | 98 (28* 3%)                                 |
| 75 mg  | 305 (82* 4%)                                | 237 (68* 5%)                                |
| 100 mg | 0                                           | 0                                           |
| missing| 18                                          | 42                                          |
|        | Week 3                                      |                                             |
| 25 mg  | 2 (0* 5%)                                   | 3 (0* 9%)                                   |
| 50 mg  | 30 (8* 2%)                                  | 49 (15* 1%)                                 |
| 75 mg  | 87 (23* 8%)                                 | 109 (33* 6%)                                |
| 100 mg | 246 (67* 4%)                                | 163 (50* 3%)                                |
| missing| 23                                          | 64                                          |
|        | Week 4                                      |                                             |
| 25 mg  | 0                                           | 2 (0* 7%)                                   |
| 50 mg  | 14 (3* 9%)                                  | 24 (8* 0%)                                  |
| 75 mg  | 50 (13* 9%)                                 | 71 (23* 6%)                                 |
| 100 mg | 296 (82* 2%)                                | 204 (67* 8%)                                |
| missing| 28                                          | 87                                          |
|        | Week 5                                      |                                             |
| 25 mg  | 0                                           | 0                                           |
| 50 mg  | 9 (2* 5%)                                   | 21 (7* 4%)                                  |
| 75 mg  | 35 (9* 8%)                                  | 52 (18* 2%)                                 |
| 100 mg | 313 (87* 7%)                                | 212 (74* 4%)                                |
| missing| 31                                          | 103                                         |
|        | Week 6                                      |                                             |
| 25 mg  | 0                                           | 0                                           |
| 50 mg  | 8 (2* 3%)                                   | 19 (6* 9%)                                  |
| 75 mg  | 35 (9* 9%)                                  | 49 (17* 8%)                                 |
| 100 mg | 310 (87* 8%)                                | 207 (75* 3%)                                |
| missing| 35                                          | 113                                         |